Juneau Biosciences Gives Four Presentations at the 66th Annual Meeting of the Society for Reproductive Investigation (SRI)

 Juneau Biosciences reports its recent findings relating to the genetics of endometriosis in four presentations at SRI

  SALT LAKE CITY, March 14, 2019 (GLOBE NEWSWIRE) — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Juneau Biosciences is delivering four scientific presentations at the 66th Annual Meeting of the Society for Reproductive Investigation (SRI), which is being held from Tuesday, March 12th to Saturday, March, 16th in Paris, France.  Predictive Technology Group inlicensed the technology supporting its ARTGuide® Test for endometriosis and other genetic causes of infertility from Juneau and is the company’s largest shareholder.

On Thursday March 14, Juneau scientists gave three presentations at the SRI meeting.  Dr. Ward, Juneau’s Founder and CEO, presented “Protein-Truncating Mutations Underlying Endometriosis.”  Protein truncating variants (PTVs) are gene mutations which usually cause a complete loss of function of the encoded protein. Finding PTVs associated with a disease can efficiently uncover novel pathophysiologic factors and important therapeutic targets. Dr. Ward reported on findings from the successful genome-wide search for PTVs associated with endometriosis conducted by Juneau.  These mutations have been incorporated in the ARTguide test currently being used for infertility patients at beta launch sites in the United States.

Dr. Ward presented a second paper describing mutations in the METTL11B gene found in familial endometriosis.  This presentation highlights how high-risk families with multiple generations of women affected by endometriosis can be studied to discover rare mutations that can play a large role in determining whether a woman descendant develops endometriosis.  This genetic sleuthing is made easier with the use of PRED’s GenDB database, which allows researchers to track relationships between 32 million ancestors and the present-day population of the Intermountain West.  This database was used to discover the largest endometriosis family in the world, with hundreds of women with a confirmed diagnosis who are all descendants of a man born in England in 1608.  This remarkable family spans 19 generations, and hundreds of thousands of women around the globe may carry endometriosis-promoting gene mutations transmitted in this family.

Dr. Hans Albertsen, Juneau’s Chief Scientific Officer, presented the third paper entitled “Avoiding False Positive Results through Ancestry Filtering.”  His presentation addressed the importance of precisely considering the ancestry of research subjects to avoid false positive conclusions when conducting genetic research studies.  He describes the care used to develop the ARTguide test, which includes over 200 DNA-based markers to determine the proper ancestral reference group when interpreting results.

On Saturday, March 16, Dr. Ward will present a paper entitled “The Genetic Architecture of Endometriosis.”  This paper will summarize over a decade of discovery work that led to a detailed understanding of the genetic factors contributing to endometriosis.

SRI is the leading international research organization in the areas of gynecology and reproductive health.  The organization seeks to advance reproductive and women’s health care through outstanding basic, translational, and clinical science and by training and mentoring future generations of investigators.

Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, recently launched its novel test for women experiencing infertility, called ARTGuide®, to selected Beta launch centers.  The ARTGuide® Test will now incorporate these latest data.  The test is expected to change the way that Advanced Reproductive Technologies (ART) such as In Vitro Fertilization (IVF) are used to help couples struggling to have a baby. Tens of thousands of women have been tested as part of this research and development program.

About Endometriosis:

Endometriosis affects more than 10 million women in the United States. Endometriosis occurs when the tissue similar to the lining of the uterus (womb), found in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.

About Juneau Biosciences:

Juneau Biosciences is a privately held medical genetics company conducting groundbreaking research to develop innovative diagnostic products for diseases that predominantly affect women. Launched in early 2007, the Salt Lake City based firm has focused so far on the development of novel molecular diagnostics and therapeutics for endometriosis, a condition estimated to affect approximately 10% of reproductive-age females.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories.  These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products.  The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.  Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

JUNEAU BIOSCIENCES TO PRESENT AT THE 66TH ANNUAL MEETING OF THE SOCIETY FOR REPRODUCTIVE INVESTIGATION (SRI)

Juneau Biosciences to discuss its recent findings relating to the genetics of endometriosis in four presentations at SRI 

Salt Lake City (March 7, 2019) — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Juneau Biosciences will deliver four scienctific presentations at the 66th Annual Meeting of the Society for Reproductive Investigation (SRI), which will be held from Tuesday, March 12th to Saturday, March, 16th in Paris, France.  Predictive Technology Group inlicensed the technology supporting its ARTGuide® Test for endometriosis and other genetic causes of infertility from Juneau and is the company’s largest shareholder.

Juneau Biosciences scientists, Kenneth Ward, M.D. and Hans Albertsen, Ph.D., will discuss Juneau’s recent findings concerning the genetics of endometriosis.

SRI is the leading international research organization in the areas of gynecology and reproductive health.  The organization seeks to advance reproductive and women’s health care through outstanding basic, translational, and clinical science and by training and mentoring future generations of investigators.

Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, recently launched its novel test for women experiencing infertility, called ARTGuide®, to selected Beta launch centers.  The ARTGuide® Test will now incorporate these latest data.  The test is expected to change the way that Advanced Reproductive Technologies (ART) such as In Vitro Fertilization (IVF) are used to help couples struggling to have a baby. Tens of thousands of women have been tested as part of this research and development program.

About Endometriosis:

Endometriosis affects more than 10 million women in the United States. Endometriosis occurs when the tissue similar to the lining of the uterus (womb), found in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.

About Juneau Biosciences:

Juneau Biosciences is a privately held medical genetics company conducting groundbreaking research to develop innovative diagnostic products for diseases that predominantly affect women. Launched in early 2007, the Salt Lake City based firm has focused so far on the development of novel molecular diagnostics and therapeutics for endometriosis, a condition estimated to affect approximately 10% of reproductive-age females.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories.  These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products.  The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.  Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Predictive Technology Group Sponsors 5th Annual Perinatal Stem Cell Society Congress

SALT LAKE CITY, March 05, 2019 (GLOBE NEWSWIRE) — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that its subsidiary Predictive Biotech sponsored the 5th Annual Perinatal Stem Cell Society Congress held February 28 through March 1, 2019 in Salt Lake City.  Predictive Biotech uses perinatal tissue to produce human cell and tissue products.

“We are pleased to have partnered with the Perinatal Stem Cell Society on this key conference that provides access to leading-edge perinatal tissue research, and a networking and collaboration opportunity for researchers and industry partners,” said Bradley C. Robinson, CEO of Predictive Technology Group.  “The science utilizing perinatal tissue is progressing at an increasingly faster pace leading to more therapeutics.  Predictive supports and is a member of the Society’s working group to bring together top clinicians and researchers to advance standards and guidelines that support the science and manufacturing of therapeutic products derived from perinatal tissue.”

“We are pleased that Predictive has joined the perinatal society as a platinum sponsor for the second year. Through Predictive’s market leadership position and commitment to advancing the science, quality and therapeutic use of perinatal tissue, we all move another step closer in delivering on the promise of these tissues,” said Kyle Cetrulo President and Founder of the Perinatal Stem Cell Society. “Attendees benefit from this open forum in a collaborative environment to discuss industry and science topics that are affecting one of the most significant medical advances of our time.”

Perinatal Stem Cell Society
The Perinatal Stem Cell Society, Inc. is a non-profit organization founded in 2013 on the basic principle that stem cells from perinatal tissues contain enormous, untapped potential to treat many diseases and disorders.  Perinatal stem cell sources include amnion, amniotic fluid, cord blood, cord tissue/Wharton’s jelly, as well as placental blood and placental tissue. Perinatal stem cells are formed around the time of birth and are classified as adult stem cells.  Yet because they are more primitive than stem cells found in bone marrow, adipose tissue or other traditional sources of adult stem cells, they have greater therapeutic potential.

About Predictive Technology Group, Inc. 
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories.  These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products.  The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.  Additional information is available at Predtechgroup.comPredrx.com and Predictivebiotech.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

Predictive Technology Group Names Jay M. Moyes to Its Board of Directors

30-year healthcare veteran brings considerable financial and governance expertise

 SALT LAKE CITY, Feb. 28, 2019– Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. His appointment expands Predictive’s Board to five.

“We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group. “Jay’s extensive financial background in companies spanning from development-stage to commercial operations in diagnostics, genetics and therapeutics makes him ideally suited for this role. His wealth of governance experience from many years on multiple healthcare Boards will be particularly valuable, and we are excited to welcome Jay to our Board.”

“I’m delighted to join this company on the cutting-edge of precision medicine,” said Moyes.  “Predictive’s approach to using proprietary, extensive genetic data analytics to bring novel diagnostics and therapeutics to underserved markets in women’s health and spinal disease positions it to make important contributions to improving health care. I look forward to working toward achieving the company’s goals.”

Moyes previously served as Chief Financial Officer and Director of the publicly traded biomaterials company Amedica Corporation, now SINTX Technologies, where he managed the company’s IPO and listing on NASDAQ, and as Chief Financial Officer at publicly traded CareDx, a molecular diagnostics company where he introduced a strategy to reach profitability. Prior to that he held senior finance positions including Chief Financial Officer during his 14-year tenure at publicly traded Myriad Genetics.  In addition to overseeing all financial aspects at Myriad as the company transitioned from 10 to more than 900 employees, he was instrumental in raising more than $500 million in public and private financings. He previously was Vice President of Finance and Chief Financial Officer of Genmark, a private genetics company. Moyes began his career in public accounting at KPMG.

Moyes serves on the Boards of Directors of Achieve Life Sciences  BioCardia, and Puma Biotechnologies.  In addition to Amedica, he previously was a director and Chairman of the Audit Committee of both Osiris Therapeutics and Integrated Diagnostics. He also served as a member of the Board of Trustees of the Utah Life Science Association. Moyes holds a BA in economics from Weber State University and an MBA from the University of Utah.

About Predictive Technology Group, Inc. 
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories.  These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products.  The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.  Additional information is available at Predtechgroup.comPredrx.com and Predictivebiotech.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Predictive Technology Group Reports Second Quarter Fiscal 2019 Financial

Revenue jumps 216% for the quarter to $10.7 million versus the prior year; and up 246% for the six month period to $18.8 million with $2.0 million in positive cash flow from operations

SALT LAKE CITY, Feb. 15, 2019 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, reports financial results for the three and six months ended December 31, 2018 and provides a business update.

Management Commentary

“I’m pleased with our financial performance with revenue for our most recent quarter of nearly $11 million, up more than three-fold from the year-ago period, marking our ninth consecutive quarter of growth,” said Bradley C. Robinson, CEO of Predictive Technology Group. “Our strong revenue performance for the quarter puts Predictive on a run rate exceeding $40 million for fiscal 2019. Additionally, we generated $2 million in positive cash flow from operations for the past six months that supported the further development and commercialization of proprietary genetic-based diagnostics and therapeutics. We completed the quarter with $2.6 million in cash and no long-term debt.

“We filed a Form 10 registration statement in December 2018 and have been fortunate to have numerous industry-leading advisors assist in guiding this process. Predictive is now a fully reporting company, providing investors with heightened transparency of our financials and operations,” he added. “Importantly, this filing is a major step in the process to list our common stock on NASDAQ, which we expect will provide greater visibility and credibility, and expand our reach to a substantially larger market.”

Recent Highlights

Corporate Developments
• Filed a Form 10 registration statement with the SEC. Predictive is now subject to the reporting requirements of the Exchange Act, including the filing of annual reports on Form 10-K, quarterly reports on Form 10-Q and periodic reports on Form 8-K, among other requirements.

• Announced John E. Sorrentino as Chairman of the Board in addition to his role as Chair of the company’s Scientific Advisory Board. Mr. Sorrentino has more than 35 years of senior management experience in the life sciences industry, including 15 years in leadership positions at Wyeth/Pfizer.

• Appointed Charles Andres, J.D., Ph.D., to its Scientific Advisory Board. Dr. Andres leads the life sciences group at Wilson Sonsini Goodrich & Rosati’s Washington, DC office and has significant expertise in intellectual property, FDA/regulatory, transactions, business and government matters.

• Completed the initial phase of its new laboratory facility featuring an ISO clean room, which meets Good Tissue Practices (GTP) and Good Manufacturing Practices (GMP) requirements for human cell and tissue products. Predictive expects phase two of the laboratory facility to be completed during second calendar quarter of 2019.

Second Quarter Fiscal 2019 Results-Click Here

Revenues from operations (net) for the three months ended December 31, 2018 totaled $10.7 million, compared with $3.4 million for the three months ended December 31, 2017. The increase of $7.3 million was the result of an expansion of our sales force and distribution networks leading to increased sales of our HCT/Ps and regenerative medicine products.

Cost of goods sold (“COGS”) includes expenses associated with acquisition and processing, manufacture (including material and direct labor), property and equipment depreciation, shipping, and other direct expenses relating to our HCT/Ps and regenerative medicine products. Our gross profit for the three months ended December 31, 2018 was $7.6 million compared with $2.5 million for the three months ended December 31, 2017. The increased gross profit resulted from increased sales and efficiencies introduced into our manufacturing processes.

Sales and marketing expenses for the three months ended December 31, 2018 were $3.4 million, compared with $953,000 for the three months ended December 31, 2017. The increased sales and marketing expenses resulted from corresponding increases in sales and an increase in the number of distributors.

Research and development (R&D) expenses for the three months ended December 31, 2018 were $1.8 million, compared with $37,000 for the three months ended December 31, 2017. The increased research and development expenses resulted from increased focus on product development, streamlining manufacturing methods and additional proprietary research and development work relating to our HCT/Ps and regenerative medicine products. Additionally, we have invested significant amounts in laboratory support in anticipation of the sale of diagnostic products.
General and Administrative (G&A) expenses for the three months ended December 31, 2018 were $2.5 million compared with $1.1 million for the three months ended December 31, 2017. The changes in general and administrative expenses resulted from increased management headcount in fiscal 2018, and stock options and warrants issued for consulting services relating to all business entities in fiscal 2017.

Amortization and depreciation expenses for the three months ended December 31, 2018 were $2.0 million, compared with $850,000 for the three months ended December 31, 2017. The reason for the increase in amortization and depreciation expenses relate primarily to the expense of costs relating to our acquisitions.

The net loss attributable to controlling interest for the three months ended December 31, 2018 was $2.6 million, or $0.01 per share, versus a net loss attributable to controlling interest for the three months ended December 31, 2018 of $376,000, or $0.00 per share.

Year-to-date Financial Results

Revenue for the first six months of fiscal 2019 was $18.8 million, a 246% increase from $5.4 million reported for the first six months of fiscal 2018. Gross profit margin for first six months of 2019 was 68.4%, an improvement from 67.5% from the prior year period.

Operating expenses for the first six months of fiscal 2019 were $17.0 million versus $9.4 million for the prior year period. The increase in the fiscal 2019 period was due to increases in sales and marketing expenses, R&D expenses, and amortization and depreciation expenses, offset in part by lower G&A expenses. For the six months ended December 31, 2018, sales and marketing expenses were $5.8 million, G&A expenses were $5.1 million, R&D expenses were $2.4 million, and amortization and depreciation expenses was $3.7 million.

The company reported an investment loss of $915,000 for the first six months of 2019. The company did not report an investment loss or gain in the prior year period.

The net loss attributable to controlling interest for the first six months of fiscal 2019 was $5.0 million, or $0.02 per share, versus a net loss attributable to controlling interest for the first six months of fiscal 2018 of $5.5 million, or $0.03 per share.

The company reported cash and cash equivalents of $2.6 million as of December 31, 2018 compared with $1.2 million as of June 30, 2018.

About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com andPredictivebiotech.com.

Financial can be viewed at THE US SEC EDGAR Site per below:
https://www.sec.gov/Archives/edgar/data/1382943/000109181819000029/pred02142019form10q.htm

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Predictive Technology Group, Inc.’s (PRED) Subsidiary Provides a Sponsorship at 4th Annual Perinatal Stem Cell Society Congress

Salt Lake City, UT- March 5, 2018- Predictive Biotech, Inc., a wholly owned subsidiary of Predictive Technology Group, Inc. (PRED.OTCPINK) provided a sponsorship at the 4th Annual Perinatal Stem Cell Society Congress, Salt Lake City, UT on March 1-2, 2018.

In 2013, the Perinatal Stem Cell Society, Inc. a non-profit organization was founded on the basic principle that stem cells from perinatal tissues contain enormous, untapped life potential to treat many diseases and disorders. Perinatal stem cell sources include: amnion, amniotic fluid, cord blood, cord tissue/Wharton’s jelly, as well as placental blood and placental tissue

Dr. Doug Schmid, Chief Science and Lab Officer, at Predictive Biotech, Inc., presented an oral presentation to the society titled: “Wharton’s Jelly: A Perinatal Cytokine Reservoir?”

Dr. Schmid received his Ph.D. in Physiology from the University of Utah School of Medicine in Salt Lake City, Utah. He completed four years of post-doctoral training at the University of Utah Medical School and five years as a Research Associate at the University of Utah Medical School as a cellular biologist. Dr. Schmid has 23 years of experience in primary cell culture, tissue processing and cryogenic storage of cells and tissues. After working at the University of Utah, from 2009 to present, Dr. Schmid has established, implemented, and supervised the operational aspects of several tissue companies, including the recovery, quality control, processing, and distribution of tissue. He is passionate about quality and vitality of physiological products and the vast benefits they deliver.

Predictive Technology Group, Inc. wholly owned subsidiary, Predictive Biotech, Inc. is in the business of developing advancements in human cell and tissue products. Data collected in collaboration with other research institutes and clients are the cornerstone in Predictive Biotech’s product development.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) RETAINS DONOHOE ADVISORY ASSOCIATES LLC, TO ASSIST IN PREPARING TO SEEK A LISTING ON A NATIONAL SECURITIES EXCHANGE

Salt Lake City, UT- February 27, 2018- Predictive Technology Group, Inc. (OTCPINK:PRED) announces that it has engaged Donohoe Advisory Associates, LLC (“Donohoe Advisory”) in connection with its efforts to seek a listing for its common shares on a national securities exchange.

Donohoe Advisory was founded by Dave Donohoe in 2004, and since that time the firm has successfully represented hundreds of companies in a wide range of listing proceedings and engagements at both Nasdaq and the NYSE. Each professional member of Donohoe Advisory’s team previously worked for either The Nasdaq Stock Market (“Nasdaq”) or the New York Stock Exchange (the “NYSE”). Prior to forming Donohoe Advisory, Dave Donohoe spent 9+ years with Nasdaq, where he ultimately served as Chief Counsel in the Listing Qualifications Department.

Bradley Robinson, CEO, Predictive Technology Group, Inc. states, “At this juncture in PRED’s corporate growth, PRED believes it is well positioned to pursue a listing on a recognized exchange. Hiring Donohoe Advisory will help to further this effort.”

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED’s subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES COMPLETION OF GENOTYPING IN TWO CLINICAL TRIALS OF ARTGUIDE™

Salt Lake City, UT — February 20, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED) announces that Predictive Therapeutics, LLC, its wholly-owned subsidiary, completed a crucial milestone in the development and commercialization of ARTGuide™.

The Company’s scientific team completed the genotyping in two clinical trials of ARTGuide™. As such, Company representatives are providing three scientific presentations at the 65th Annual Meeting of the Society for Reproductive Investigation (SRI) on March 9th and 10th in San Diego, CA.

Predictive Therapeutics, LLC anticipates its launch of a novel test for women experiencing infertility, as a result of endometriosis and other health concerns, called ARTGuide™. The test is expected to change the way Advanced Reproductive Technologies (ART), such as In Vitro Fertilization (IVF), are used to help couples struggling to have a baby. After testing thousands of women as part of the development program, the Company now expects commercial launch of the ARTGuide™ infertility test in the United States during Q3 2018.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis and pelvic pain.

PRED and its subsidiaries remain leaders in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments.

About Endometriosis:

Endometriosis affects more than 10 million women in the United States. Endometriosis occurs when the tissue similar to the lining of the uterus (womb), found in other parts of the body -most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.

About Predictive Technology Group, Inc.:
Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Pelvic Pain, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) APPOINTS RONALD BARHORST TO CHAIR ITS FINANCIAL ADVISORY BOARD

Salt Lake City, UT — January 30, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments, announces that its Financial Advisory Board appointed Mr. Ronald Barhorst as Chairman. Mr. Barhorst brings in depth finance and governance experience gained during a career in the financial markets.

In January 2013, after 25 years in the financial services industry, Mr. Barhorst retired as President and CEO of ING Financial Advisers, LLC, Systematized Benefits Administrators, Inc., and ING Investment Advisors, LLC. Mr. Barhorst served as a director of ING Life Insurance Holding Company, Inc. and as an officer of several other ING companies. Mr. Barhorst currently serves as Chairman of the California State University Foundation Board of Governors, a position he has held for the past 15 years.

“I have had the opportunity to work with Predictive Technology Group or their predecessor companies for the past 8 years,” said Ronald Barhorst. “I am impressed with the brilliant minds that drive this Company and the substantial impact that this Company represents in targeted gene based therapeutics and women’s health.”

“As we move forward to becoming a full-reporting company under the Securities Exchange Act of 1934, Ron’s wealth of experience, gained in senior executive roles in the financial industry, will help ensure PRED maintains proper governance, oversight and guidance through its Board and Committees,” said Bradley Robinson, CEO of Predictive Technology Group.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP APPOINTS DR. GREGORY A. PRINCE TO ITS SCIENTIFIC ADVISORY BOARD

Salt Lake City, UT — January 17, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments, announces that Dr. Gregory A. Prince will join PRED’s Scientific Advisory Board.  As a co-founder and CEO of Virion Systems, Inc., Dr. Prince brings pharmaceutical research and development and commercialization expertise to the Scientific Advisory Board team.

After earning doctorate degrees at UCLA (DDS, 1973; PhD, 1975) and serving a post-doctoral fellowship at the National Institutes of Health, Dr. Prince spent four decades in virology research, with a focus on the respiratory syncytial virus (RSV). He pioneered the prevention of RSV disease in high-risk infants, and as co-founder and CEO of Virion Systems, Inc. worked with MedImmune (acquired by AstraZeneca in 2007) to develop Synagis®. AstraZeneca markets Synagis within the United States, while AbbVie markets Synagis in all other regions.

“I welcome Greg to the PRED team.  His vision and experience in applying data analytics for disease identification and understanding of the individual will help ensure each and every patient receives the most appropriate therapy at the earliest possible point of intervention,” said Bradley Robinson, CEO, Predictive Technology Group, Inc. “Dr. Prince has already contributed greatly to society and the health of newborns, he is passionate about applying his career knowledge to improve quality of life in other population groups.”

Dixie State University-St. George, Utah inducted Dr. Prince to its Hall of Fame in 1999, in recognition of his scientific achievements, and later in 2012, the university granted him an honorary Doctorate of Humanities.  Dr. Prince serves on the national advisory councils at four universities, and as the governor of Wesley Theological Seminary in Washington, D.C. He holds adjunct professorships at UCLA and Dixie State University and currently serves as Chief Scientific Officer at Soft Cell Biological Research, LLC.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.